2016 Hematological Malignancies

Phase 1b KEYNOTE-013 KEYTRUDA

(Pembrolizumab),

Anti-PD-1 Therapy, in Relapsed/Refractory Classical Hodgkin Lymphoma

• P

embrolizumab

10 mg/kg every two weeks relapsed/refractory classical HL progressed

after brentuximab vedotin after failure of ASCT, or transplant-ineligible (n=29).

• Median time to response was 12 weeks

• Adverse events (≥2 patients) included hypothyroidism (n=3), pneumonitis (n=3),

constipation (n=2), diarrhea (n=2), nausea (n=2), hypercholesterolemia (n=2),

hypertriglyceridemia (n=2) and hematuria (n=2)

• Sixteen patients (55%) experienced at least one treatment-related adverse event of any

grade

– Grade 3 AEs in 3 patients: axillary pain, hypoxia, joint swelling, and pneumonitis; no Grade 4 AEs

reported

PD1 – programmed death 1; ASCT – autologous stem cell

transplantation; AEs – adverse events

Moskowitz C et al. ASH 2014. Oral 290